Is 1.7mg Wegovy a strong dose, or just a stepping stone?

What the clinical evidence was actually built on

The headline weight-loss figures most people read about Wegovy come from STEP 1, a 68-week randomised controlled trial in adults with obesity or overweight and at least one weight-related condition, published in the New England Journal of Medicine. Participants reached 2.4mg as their maintenance dose. That is the dose linked to approximately 15% average body-weight reduction. The 1.7mg stage was part of the gradual escalation used to get there, not a dose tested for long-term outcomes in its own right.

That distinction matters. It means the question "is 1.7mg Wegovy strong?" is a bit like asking whether the fourth gear of a car is powerful, it depends where you are going and what comes next. At 1.7mg your appetite suppression is real and your system is adapting, but the full therapeutic picture the trials describe belongs to the 2.4mg level.

The NHS medicines page for semaglutide confirms the titration pathway as a standard part of treatment, rather than an optional phase you can skip.

Why the titration exists and what happens at 1.7mg

Wegovy's dose escalation is there for a practical reason: GI side effects such as nausea, loose stools and indigestion are most likely to appear when the dose goes up. Stepping through 0.25mg, 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg gives the body time to adjust. At 1.7mg many people find the side-effect burden has settled compared with earlier increases, which is precisely why this level sometimes feels like a plateau before the final step.

It is worth knowing that some patients remain at 1.7mg for longer than the standard four-week window. If a dose increase triggered significant nausea or other symptoms, a prescriber may decide an extended stay at 1.7mg is the right call before moving up. That is not a failure of the treatment, it is the dose schedule working as intended. The Wegovy doses guide walks through each level and what to expect.

For comparison, those now on the newer 7.2mg pen approved by the MHRA in April 2026 started at exactly the same 0.25mg beginning and reached 2.4mg first. Higher is not always better; it is always a clinical judgement.

Does staying at 1.7mg affect your results?

Short answer: possibly, compared with 2.4mg, but individual response varies considerably. The trial data are clear that 2.4mg produced the average 15% reduction figure, but averages hide a wide spread. Some people lose more than the average at 2.4mg; some lose less; a small number respond strongly at lower doses.

If your prescriber has moved you to 1.7mg and is monitoring your progress, the question they will ask is whether you are losing weight steadily and tolerating the dose well. NICE guidance for semaglutide (TA875) notes that if fewer than 5% weight loss has occurred after six months on the maintenance dose, continuing should be reviewed. That assessment belongs with a clinician, not a milligram number alone.

One practical note worth keeping in mind: your Wegovy pen lives in the fridge between doses, so a good habit is storing it at eye level in the fridge door where you will not forget it, the same applies at 1.7mg as it does at any other dose. Always check your patient information leaflet for the exact room-temperature window if you need to travel.

If you want to understand how 1.7mg compares to where the dose ladder ends, the page on whether 2.4mg Wegovy is strong gives a detailed look at the maintenance evidence. And if you are still in the earlier phases, the 1mg Wegovy dose page covers what that stage typically means for patients.

Getting onto, or continuing, treatment at the right dose

Wegovy is a prescription-only medicine. No one should be adjusting their dose based on what they read online, including this page. What belongs here is the evidence; what belongs with a prescriber is the decision about your individual dose.

At nume, every repeat order involves a fresh clinical review by a GPhC-registered Independent Prescriber (a real person reading your notes) before anything is dispensed. There is no auto-renewal and no algorithm making dose decisions. If you are thinking about starting treatment or moving to the next dose level, you can see what the consultation process looks like on our weight-loss treatments page.

For context on what treatment costs as a private patient, the Wegovy cost page sets out the pricing picture honestly. And for a fuller read on how Wegovy compares with other options and what it is designed to do, the weight-loss treatments overview is a good place to start. Our FAQs cover a lot of the practical questions that come up once you are on treatment.

Check your eligibility with our clinical team if you want a proper assessment of where you are in your treatment journey.